CTLA4 and cancer: Recently, immune checkpoint treatments targeting programmed cell death 1/programmed cell death-ligand 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) have been rapidly developed as therapeutic approaches for cancer.